Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kohei Shitara

Showing results (211-220 of 344) with videos related to

Pageof 35
Sort By:
Cancer Science|October 7, 2016
Randomized study of FOLFIRI plus either panitumumab or bevacizumab for wild-type KRAS colorectal cancer-WJOG 6210GKohei Shitara, Kimio Yonesaka, Tadamichi Denda, et al.
Cancer Medicine|July 22, 2022
Liposomal eribulin for advanced adenoid cystic carcinoma, gastric cancer, esophageal cancer, and small cell lung cancerHibiki Udagawa, Shunji Takahashi, Motohiro Hirao, et al.
Scientific Reports|September 25, 2023
p70S6K/Akt dual inhibitor DIACC3010 is efficacious in preclinical models of gastric cancer alone and in combination with trastuzumabShota Fukuoka, Yoshikatsu Koga, Mayumi Yamauchi, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|May 15, 2025
A phase Ib study of photoimmunotherapy with ASP-1929 in combination with nivolumab for advanced gastric cancer (GE-PIT, EPOC1901)Tomohiro Kadota, Rika Fujii, Shohei Koyama, et al.
Asian Pacific Journal of Cancer Prevention : APJCP|September 17, 2010
Effects of genetic polymorphisms in the ABCB1 gene on clinical outcomes in patients with gastric cancer treated by second-line chemotherapyKohei Shitara, Keitaro Matsuo, Seiji Ito, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 1, 2021
TAS-116 (Pimitespib), an Oral HSP90 Inhibitor, in Combination with Nivolumab in Patients with Colorectal Cancer and Other Solid Tumors: An Open-Label, Dose-Finding, and Expansion Phase Ib Trial (EPOC1704)Akihito Kawazoe, Kota Itahashi, Noboru Yamamoto, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|October 14, 2011
Combination chemotherapy with S-1 plus cisplatin for gastric cancer that recurs after adjuvant chemotherapy with S-1: multi-institutional retrospective analysisKohei Shitara, Satoshi Morita, Kazumasa Fujitani, et al.
Cancer Immunology Research|November 27, 2024
The HSP90 Inhibitor Pimitespib Targets Regulatory T Cells in the Tumor MicroenvironmentAyaka Tsuge, Sho Watanabe, Akihito Kawazoe, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 30, 2021
A Low Tumor Mutational Burden and <i>PTEN</i> Mutations Are Predictors of a Negative Response to PD-1 Blockade in MSI-H/dMMR Gastrointestinal TumorsKeigo Chida, Akihito Kawazoe, Masahito Kawazu, et al.
The Lancet. Oncology|October 18, 2017
Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody-drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation studyToshihiko Doi, Kohei Shitara, Yoichi Naito, et al.
Pageof 35

Showing results (211-220 of 344) with videos related to

Sort By:
Pageof 35
Cancer Science|October 7, 2016
Randomized study of FOLFIRI plus either panitumumab or bevacizumab for wild-type KRAS colorectal cancer-WJOG 6210GKohei Shitara, Kimio Yonesaka, Tadamichi Denda, et al.
Cancer Medicine|July 22, 2022
Liposomal eribulin for advanced adenoid cystic carcinoma, gastric cancer, esophageal cancer, and small cell lung cancerHibiki Udagawa, Shunji Takahashi, Motohiro Hirao, et al.
Scientific Reports|September 25, 2023
p70S6K/Akt dual inhibitor DIACC3010 is efficacious in preclinical models of gastric cancer alone and in combination with trastuzumabShota Fukuoka, Yoshikatsu Koga, Mayumi Yamauchi, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|May 15, 2025
A phase Ib study of photoimmunotherapy with ASP-1929 in combination with nivolumab for advanced gastric cancer (GE-PIT, EPOC1901)Tomohiro Kadota, Rika Fujii, Shohei Koyama, et al.
Asian Pacific Journal of Cancer Prevention : APJCP|September 17, 2010
Effects of genetic polymorphisms in the ABCB1 gene on clinical outcomes in patients with gastric cancer treated by second-line chemotherapyKohei Shitara, Keitaro Matsuo, Seiji Ito, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 1, 2021
TAS-116 (Pimitespib), an Oral HSP90 Inhibitor, in Combination with Nivolumab in Patients with Colorectal Cancer and Other Solid Tumors: An Open-Label, Dose-Finding, and Expansion Phase Ib Trial (EPOC1704)Akihito Kawazoe, Kota Itahashi, Noboru Yamamoto, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|October 14, 2011
Combination chemotherapy with S-1 plus cisplatin for gastric cancer that recurs after adjuvant chemotherapy with S-1: multi-institutional retrospective analysisKohei Shitara, Satoshi Morita, Kazumasa Fujitani, et al.
Cancer Immunology Research|November 27, 2024
The HSP90 Inhibitor Pimitespib Targets Regulatory T Cells in the Tumor MicroenvironmentAyaka Tsuge, Sho Watanabe, Akihito Kawazoe, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 30, 2021
A Low Tumor Mutational Burden and <i>PTEN</i> Mutations Are Predictors of a Negative Response to PD-1 Blockade in MSI-H/dMMR Gastrointestinal TumorsKeigo Chida, Akihito Kawazoe, Masahito Kawazu, et al.
The Lancet. Oncology|October 18, 2017
Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody-drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation studyToshihiko Doi, Kohei Shitara, Yoichi Naito, et al.
Pageof 35